Leuprolide

Generic Name
Leuprolide
Brand Names
Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
Drug Type
Small Molecule
Chemical Formula
C59H84N16O12
CAS Number
53714-56-0
Unique Ingredient Identifier
EFY6W0M8TG
Background

Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...

Indication

Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.

It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...

Associated Conditions
Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

Phase 4
Completed
Conditions
Central Precocious Puberty
Interventions
Drug: Leuprorelin
First Posted Date
2015-04-28
Last Posted Date
2022-03-16
Lead Sponsor
Takeda
Target Recruit Count
307
Registration Number
NCT02427958

Micro RNAs to Predict Response to Androgen Deprivation Therapy

First Posted Date
2015-02-19
Last Posted Date
2024-11-25
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
42
Registration Number
NCT02366494
Locations
🇺🇸

Froedtert Hospital, Milwaukee, Wisconsin, United States

Detect V / CHEVENDO (Chemo vs. Endo)

First Posted Date
2015-01-26
Last Posted Date
2024-06-04
Lead Sponsor
Prof. Wolfgang Janni
Target Recruit Count
271
Registration Number
NCT02344472
Locations
🇩🇪

University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany

Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Drug: ELIGARD
First Posted Date
2014-10-24
Last Posted Date
2023-08-01
Lead Sponsor
Institut Cancerologie de l'Ouest
Target Recruit Count
70
Registration Number
NCT02274779
Locations
🇫🇷

ICO Paul Papin, Angers, France

🇫🇷

ICO René Gauducheau, Saint-Herblain, France

Testosterone Regulation of the Natriuretic Peptide System

First Posted Date
2014-10-20
Last Posted Date
2017-10-19
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT02269072

GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles

Phase 3
Conditions
Infertility
Interventions
Drug: leuprolide
First Posted Date
2014-10-13
Last Posted Date
2014-10-13
Lead Sponsor
Queensland Fertility Group
Target Recruit Count
200
Registration Number
NCT02262416
Locations
🇦🇺

Queensland Fertility Group, Brisbane, Queensland, Australia

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"

Completed
Conditions
Prostate Cancer
Interventions
Drug: Leuprorelin acetate
First Posted Date
2014-06-19
Last Posted Date
2017-03-29
Lead Sponsor
Takeda
Target Recruit Count
11288
Registration Number
NCT02167893

Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

Completed
Conditions
Breast Cancer
Interventions
Drug: Leuprorelin acetate
First Posted Date
2014-06-03
Last Posted Date
2016-02-17
Lead Sponsor
Takeda
Target Recruit Count
651
Registration Number
NCT02154139

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"

Completed
Conditions
Breast Cancer
Interventions
Drug: Leuprorelin Acetate
First Posted Date
2014-05-09
Last Posted Date
2016-10-18
Lead Sponsor
Takeda
Target Recruit Count
2816
Registration Number
NCT02134977

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: Leuprorelin
Drug: Bicalutamide
First Posted Date
2014-03-12
Last Posted Date
2019-06-28
Lead Sponsor
Takeda
Target Recruit Count
116
Registration Number
NCT02085252
Locations
🇫🇷

Ouzid, Paris La Défense,, Paris, France

🇫🇷

Tenon Hospital Paris France, Paris, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy